Targeting Novel Eph Receptors in Solid Tumours

This project is suitable for PhD students.

BACKGROUND

We have generated well-characterised monoclonal antibodies (mAbs) against several Eph and ephrin receptor proteins that are present on distinct cell populations in several solid tumours such as colon, breast, prostate and brain cancer. We plan to use these novel mAbs to effectively target these aggressive treatment refractory cancers. By targeting these tumour-specific proteins and not normal tissues, we aim to reduce toxicity while effectively boosting efficacy. We have conjugated these mAbs with cytotoxic drugs to deliver them as antibody drug conjugates (ADCs). This project will aim to test ADC efficacy in vitro and in preclinical animal models.

AIM

To validate Eph receptor ADCs as effective therapies for the treatment of aggressive solid tumours in vitro and in vivo.

APPROACH

• In vitro assays to determine cell killing and IC₅₀
• Apoptosis/Cell death assays
• Flow cytometry and Western blotting
• Immunofluorescence and confocal microscopy
• Preclinical animal experimentation

EXPECTED OUTCOME

Validation of novel ADCs that have anti-cancer effects in solid tumour cell line models which would then serve as a platfform for further validation in pre-clinical animal models. This would pave the way for translation into the clinic to improve outcomes for patients affected with these treatment refractory diseases.